Status:
COMPLETED
Effect of Cyclosporine on the Pharmacokinetics (PK) of AT-527 (R07496998)
Lead Sponsor:
Atea Pharmaceuticals, Inc.
Collaborating Sponsors:
Hoffmann-La Roche
Conditions:
Healthy Volunteer Study
Eligibility:
MALE
18-65 years
Phase:
PHASE1
Brief Summary
This study will determine the effect of cyclosporine on the PK of AT-527 (R07496998) in healthy male subjects
Eligibility Criteria
Inclusion
- Must agree to use two methods of birth control from Screening through 90 days after administration of the last dose of study drug
- Minimum body weight of 50 kg and body mass index (BMI) of 18-29 kg/m2
- Willing to comply with the study requirements and to provide written informed consent
Exclusion
- Infected with hepatitis B virus, hepatitis C virus, HIV or SARS-CoV-2
- Abuse of alcohol or drugs
- Use of other investigational drugs within 28 days of dosing
- Concomitant use of prescription medications, or systemic over-the-counter medications
- Other clinically significant medical conditions or laboratory abnormalities
Key Trial Info
Start Date :
April 18 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 10 2021
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT04849299
Start Date
April 18 2021
End Date
May 10 2021
Last Update
August 2 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Atea Study Site
Montreal, Quebec, Canada